Increased frequency of Mediterranean fever gene variants in multiple myeloma

Celik,Serkan; Tangi,Fatih; Oktenli,Cagatay

doi:10.3892/ol.2014.2407

Increased frequency of Mediterranean fever gene variants in multiple myeloma

Authors:
- Serkan Celik
- Fatih Tangi
- Cagatay Oktenli
View Affiliations

Affiliations: Division of Oncology, GATA Haydarpasa Training Hospital, Istanbul, Turkey, Division of Internal Medicine, GATA Haydarpasa Training Hospital, Istanbul, Turkey, Department of Internal Medicine, Anadolu Medical Center, Kocaeli, Turkey
Published online on: August 4, 2014 https://doi.org/10.3892/ol.2014.2407
Pages: 1735-1738

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

High frequencies of inherited variants in the Mediterranean fever (MEFV) gene have been identified in patients with multiple myeloma (MM). The sample size of the present pilot study was small, therefore, the actual frequency of inherited variants in the MEFV gene could be investigated in patients with MM. Twenty‑eight patients with MM and 65 healthy controls were included in the study. Six heterozygous and one homozygous (E148Q/E148Q) variant was identified in patients with MM. None of the patients had a family history compatible with familial Mediterranean fever. In the healthy control group, 11 heterozygous variants were identified. The difference in the overall frequency of the inherited variants in the MEFV gene between the MM patients and the controls was statistically significant (χ2=4.905; P=0.027). In conclusion, a high frequency of inherited variants in the MEFV gene was identified in patients with MM. Based on the current data, it is hypothesized that the MEFV gene is a cancer susceptibility gene. Additional evidence, such as familial aggregation, monozygotic versus dizygotic twin concordance, and tumors in genetically engineered model organisms, is required in order to support this hypothesis.

View Figures

View References

1	Celik S, Oktenli C, Terekeci HM, et al: Blood oxidative stress biomarkers in patients with familial Mediterranean fever. Akt Rheumatol. 35:382–385. 2010.
2	Terekeci HM, Oktenli C, Ozgurtas T, et al: Increased asymmetric dimethylarginine levels in young men with familial Mediterranean fever (FMF): is it early evidence of interaction between inflammation and endothelial dysfunction in FMF? J Rheum. 35:2024–2029. 2008.
3	Terekeci HM, Ulusoy ER, Kucukarslan NM, Nalbant S and Oktenli C: Familial Mediterranean fever attacks do not alter functional and morphologic tissue Doppler echocardiographic parameters. Rheum Int. 28:1239–1243. 2008.
4	Musabak U, Sengul A, Oktenli C, et al: Does immune activation continue during an attack-free period in familial Mediterranean fever? Clin Exp Immunol. 138:526–533. 2004.
5	Chae JJ, Cho YH, Lee GS, et al: Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1β activation and severe autoinflammation in mice. Immunity. 34:755–768. 2011.
6	Koc B, Oktenli C, Bulucu F, et al: The rate of pyrin mutations in critically ill patients with systemic inflammatory response syndrome and sepsis: a pilot study. J Rheumatol. 34:2070–2075. 2007.
7	Centola M, Aksentijevich I and Kastner DL: The hereditary periodic fever syndromes: molecular analysis of a new family of inflammatory diseases. Hum Mol Genet. 7:1581–1588. 1998.
8	Diaz A, Hu C, Kastner DL, et al: Lipopolysaccharide-induced expression of multiple alternatively spliced MEFV transcripts in human synovial fibroblasts: a prominent splice isoform lacks the C-terminal domain that is highly mutated in familial Mediterranean fever. Arthritis Rheum. 50:3679–3689. 2004.
9	French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet. 17:25–31. 1997.
10	The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell. 90:797–807. 1997.
11	Touitou I: The spectrum of Familial Mediterranean Fever (FMF) mutations. Eur J Hum Genet. 9:473–483. 2001.
12	Bertin J and DiStefano PS: The PYRIN domain: a novel motif found in apoptosis and inflammation proteins. Cell Death Differ. 7:1273–1274. 2000.
13	Martinon F, Hofmann K and Tschopp J: The pyrin domain: a possible member of the death domain fold family implicated in apoptosis and inflammation. Curr Biol. 11:R118–R120. 2001.
14	Schaner P, Richards N, Wadhwa A, et al: Episodic evolution of pyrin in primates: human mutations recapitulate ancestral amino acid states. Nat Genet. 27:318–321. 2001.
15	Srinivasula SM, Poyet JL, Razmara M, et al: The PYRIN-CARD protein ASC is an activating adaptor for caspase-1. J Biol Chem. 277:21119–21122. 2002.
16	Chae JJ, Wood G, Richard K, et al: The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-kappaB through its N-terminal fragment. Blood. 112:1794–1803. 2008.
17	Fernandes-Alnemri T, Wu J, Yu JW, et al: The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ. 14:1590–1604. 2007.
18	Manji GA, Wang L, Geddes BJ, et al: PYPAF1, a PYRIN-containing Apaf1-like protein that assembles with ASC and regulates activation of NF-kappa B. J Biol Chem. 277:11570–11575. 2002.
19	Matsushita K, Takeoka M, Sagara J, et al: A splice variant of ASC regulates IL-1beta release and aggregates differently from intact ASC. Mediators Inflamm. 2009:2873872009.
20	Stehlik C, Fiorentino L, Dorfleutner A, et al: The PAAD/PYRIN-family protein ASC is a dual regulator of a conserved step in nuclear factor kappaB activation pathways. J Exp Med. 196:1605–1615. 2002.
21	Papin S, Cuenin S, Agostini L, et al: The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1beta processing. Cell Death Differ. 14:1457–1466. 2007.
22	Stojanov S and Kastner DL: Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol. 17:586–599. 2005.
23	Hallek M, Bergsagel PL and Anderson KC: Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 91:3–21. 1998.
24	Li ZW, Chen H, Campbella RA, Bonavidab B and Berensona JR: NF-kappaB in the pathogenesis and treatment of multiple myeloma. Curr Opin Hematol. 15:391–399. 2008.
25	Annunziata CM, Davis RE, Demchenko Y, et al: Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 12:115–130. 2007.
26	Keats JJ, Fonseca R, Chesi M, et al: Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 12:131–144. 2007.
27	Oktenli C, Sayan O, Celik S, et al: High frequency of MEFV gene mutations in patients with myeloid neoplasm. Int J Hematol. 91:758–761. 2010.
28	Celik S, Erikci AA, Tunca Y, et al: The rate of MEFV gene mutations in hematolymphoid neoplasms. Int J Immunogenet. 37:387–391. 2010.
29	Sayan O, Kilicaslan E, Celik S, et al: High frequency of inherited variants in the MEFV gene in acute lymphocytic leukemia. Indian J Hematol Blood Transfus. 27:164–168. 2011.
30	Celik S, Oktenli C, Kilicaslan E, et al: Frequency of inherited variants in the MEFV gene in myelodysplastic syndrome and acute myeloid leukemia. Int J Hematol. 95:285–290. 2012.
31	Oktenli C and Celik S: High frequency of inherited variants in the MEFV gene in patients with hematologic neoplasms: a genetic susceptibility? Int J Hematol. 95:380–385. 2012.
32	Vangsted AJ, Nielsen KR, Klausen TW, et al: A functional polymorphism in the promoter region of the IL-1B gene is associated with risk of multiple myeloma. Br J Haematol. 158:515–518. 2012.
33	Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 100:57–70. 2000.
34	Bottero V, Withoff S and Verma IM: NF-kappaB and the regulation of hematopoiesis. Cell Death Differ. 13:785–797. 2006.
35	Grossmann M, Metcalf D, Merryfull J, et al: The combined absence of the transcription factors Rel and RelA leads to multiple hemopoietic cell defects. Proc Natl Acad Sci USA. 96:11848–11853. 1999.
36	Siebenlist U, Brown K and Claudio E: Control of lymphocyte development by nuclear factor-kappaB. Nat Rev Immunol. 5:435–445. 2005.
37	Karin M and Greten FR: NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 5:749–759. 2005.
38	Keutgens A, Robert I, Viatour P and Chariot A: Deregulated NF-kappaB activity in haematological malignancies. Biochem Pharmacol. 72:1069–1080. 2006.
39	Stoffel A: The NF-kappaB signalling pathway: a therapeutic target in lymphoid malignancies? Expert Opin Ther Targets. 9:1045–1061. 2005.
40	Salem K, Brown CO, Schibler J and Goel A: Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity. Exp Hematol. 41:209–218. 2013.
41	Ni H, Ergin M, Huang Q, et al: Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis. Br J Haematol. 115:279–286. 2001.
42	Bharti AC, Donato N, Singh S and Aggarwal BB: Curcumin (diferuloylmethane), down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood. 101:1053–1062. 2003.